Qualification of translational safety biomarkers

被引：6

作者：

Sauer, John-Michael ^{[1
]}

Porter, Amy C. ^{[1
]}

机构：

[1] Crit Path Inst, Predict Safety Testing Consortium, Biomarkers Program, Tucson, AZ 85718 USA

来源：

EXPERIMENTAL BIOLOGY AND MEDICINE | 2021年 / 246卷 / 22期

关键词：

Biomarker qualification; safety biomarkers; novel methodologies; drug-induced tissue injury; translational biomarkers; drug development tools;

D O I：

10.1177/15353702211002153

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Safety biomarkers are important drug development tools, both preclinically and clinically. It is a straightforward process to correlate the performance of nonclinical safety biomarkers with histopathology, and ideally, the biomarker is useful in all species commonly used in safety assessment. In clinical validation studies, where histopathology is not feasible, safety biomarkers are compared to the response of standard biomarkers and/or to clinical adjudication. Worldwide, regulatory agencies have put in place processes to qualify biomarkers to provide confidence in the manner of use and interpretation of biomarker data in drug development studies. This paper describes currently qualified safety biomarkers which can be utilized to monitor for nephrotoxicity and cardiotoxicity and ongoing projects to qualify safety biomarkers for liver, skeletal muscle, and vascular injury. In many cases, the development and use of these critical drug development tools is dependent upon partnerships and the precompetitive sharing of data to support qualification efforts.

引用

页码：2391 / 2398

页数：8

共 31 条

[1] Biomarker Assay Collaborative Evidentiary Considerations Writing Group, 2016, CRIT PATH I C PATH S
[2] Collins S., 2018, LOWER COST EFFICACOU
[3] EMA, 2017, LETT SUPP GLUT DEH B
[4] European Medicines Agency, 2020, QUAL NOV METH MED DE
[5] European Medicines Agency, 2014, Qualification of novel methodologies for drug development: guidance to applicants
[6] European Medicines Agency, 2009, EMA FIN CONCL PIL JO
[7] Evidentiary Criteria Writing Group, 2016, FRAM DEF EV CRIT BIO
[8] FDA-NIH Biomarker Working Group, 2016, BEST (Biomarkers, EndpointS, and other Tools) Resource
[9] Japan Pharmaceuticals and Medical Devices Agency, 2010, PMDA REC CONS PHARM
[10] What evidence do we need for biomarker qualification?
Leptak, Chris
Menetski, Joseph P.
Wagner, John A.
Aubrecht, Jiri
Brady, Linda
Brumfield, Martha
Chin, William W.
Hoffmann, Steve
Kelloff, Gary
Lavezzari, Gabriela
Ranganathan, Rajesh
Sauer, John-Michael
Sistare, Frank D.
Zabka, Tanja
Wholley, David
[J]. SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (417)

← 1 2 3 4 →